The trial is set to read out topline data in the second half of 2023 after completing the target enrollment of 73 patients with Duchenne muscular dystrophy aged 6 to 12 years. The connective tissue growth factor inhibitor has been granted orphan drug, fast track, and rare pediatric disease designations.
The associate clinical professor at the University of South Carolina School of Medicine discussed how JZP-258’s clinical profile has expanded since its original approval for narcolepsy, and whether it makes sense for all patients to consider. [WATCH TIME: 3 minutes]
Compared with normal sleepers, those with poor sleep and insomnia showed a significant association with lower flow-mediated disease levels, the most common method to describe endothelial dysfunction.
Daniel Kantor, MD, discussed his presentation at the 2022 CMSC annual meeting on COVID-19 vaccine response in patients with multiple sclerosis who are being treated with sphingosine 1 phosphate receptor modulators.
The associate clinical professor at the University of South Carolina School of Medicine provided context on 2 analyses presented at SLEEP 2022 that highlighted JZP-258’s impact in patients with idiopathic hypersomnia. [WATCH TIME: 2 minutes]
Patients with moderate-severe compared with normal-to-mild sleep disturbances had worse GAD-2 questionnaire scores, PHQ-2 scores, and PROMIS fatigue scores with no difference in age, sex, or hospitalization due to COVID-19.
Richard Finkel, MD, RAINBOWFISH’s principal investigator and the director of the Experimental Neuroscience Program at St. Jude Children’s Research Hospital, offered his take on the recent FDA decision for risdiplam (Evrysdi; Genentech).
The graduate student at the University of Michigan provided insight on her study examining longitudinal patterns of difficulty initiating sleep and their associations with subsequent memory trajectories among different races and genders. [WATCH TIME: 3 minutes]
The head of the MS Center at the University of Basel discussed an analysis presented at CMSC’s Annual Meeting, focusing on the effects of BTK inhibitor evobrutinib on neurofilament light levels.
Jeffrey Cohen, MD, spoke about the topic of his CMSC Presidential Lecture at the 2022 annual meeting, stem cell transplantation in multiple sclerosis, and what questions remain unanswered in this realm of treatment.
Mind Moments®, a podcast from NeurologyLive®, brings you a special episode recap of aducanumab's journey from discovery to present, ahead of the June 2022 issue's in-depth cover story on the topic. [LISTEN TIME: 10 minutes]
After 30 days of the PennPALS system, 70.8% of the remaining 24 patients were adherent to treatment or were using their PAP machine for at least 4 hours/night on average over the last 7 days.
The director of the Sleep Disorders program at the University of Miami discussed his research regarding the association of sleep disordered breathing and total brain volumes in Latino individuals. [WATCH TIME: 3 minutes]
The assistant professor of neurology at the University of Michigan provided context on a previous study which suggested that treatment of obstructive sleep apnea may reduce the risk of subsequent dementia. [WATCH TIME: 3 minutes]
Among those observed in the trial, Black pregnant women had a mean number of 4.20 sessions of cognitive behavioral therapy compared with 5.54 for White pregnant women.
Jeffrey Cohen, MD, shared his perspective on the current use and study of stem cells for the treatment of multiple sclerosis, which he covered in the CMSC Presidential Lecture at the 2022 annual meeting.
In subanalyses of ISI responders with chronic insomnia, those in the lemborexant 10-mg group demonstrated significantly greater changes from baseline in sleep onset latency compared with placebo.
The IDSIQ showed score changes that correlated with clinically meaningful improvement on various responder definition estimates following triangulation.
Here's what is coming soon to NeurologyLive®.
A combination of less sleep and high cardiovascular disease risk tended to be associated with greater decline in executive function.
In comparison to White participants, non-Hispanic Black individuals reported shorter sleep duration and more sleep disturbances while the opposite was observed for Hispanic individuals.
Overall, 49% of respondents with idiopathic hypersomnia were reportedly dissatisfied with the management of their condition.
Although the sample size was relatively small, the findings provide insight into predictors of adherence to CPAP, which has been known to limit the effectiveness of the therapy.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.
Between those treated with CPAP and those who withdrew treatment, the difference in N3 sleep represented 15.7% of variance beyond a base model that included age and sex alone.
Avoidance of cardiovascular issues and effects, as well as improved effort to gain control of narcolepsy symptoms, were among the reasons for switching to lower sodium oxybate.
The postdoctoral researcher at the Johns Hopkins Multiple Sclerosis Center shared his perspective on the use of spinal cord atrophy in clinical practice to measure disease progression in MS and how it might become more accessible. [WATCH TIME: 4 minutes]
After a previous analysis showed that natalizumab dosing every 6 weeks can decrease the risk of progressive multifocal leukoencephalopathy, new data showed no differences in patient-reported outcomes vs treatment every 4 weeks.
Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Riley Bove, MD; Blake E. Dewey, PhD; Bruce Cree, MD, PhD, MAS; John DeLuca, PhD; Shuvro Roy, MD; and Tanuja Chitnis, MD. [LISTEN TIME: 26 minutes]
The online tool was evaluated in a cohort of 501 patients and healthcare providers, showing positive trends in 9 of 11 outcomes assessed. Notably, disease-modifying therapy start, adherence, and long-term mental health were all improved in the intervention group.
